Scholar Rock（SRRK）因FDA批准Isembyld用于脊髓性肌萎缩症而飙升12%
· seekingalpha.com
美国食品药品监督管理局（FDA）批准Isembyld用于治疗脊髓性肌萎缩症（SMA）后，Scholar Rock（SRRK）股价上涨。
Scholar Rock Holding (SRRK) surged 12% in extended trading Friday after the Food and Drug Administration approved isembyld, the company’s treatment for spinal...